Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 1.00 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 1.00 |
| ▸ | S1PR1 | P21453 | 11/20 | 0.78 |
| ▸ | S1PR3 | Q99500 | 10/20 | 0.78 |
| ▸ | S1PR4 | O95977 | 7/20 | 0.78 |
| ▸ | TNNC1 | P63316 | 6/20 | 0.78 |
| ▸ | S1PR5 | Q9H228 | 5/20 | 0.78 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.78 |
| ▸ | GPR183 | P32249 | 1/20 | 0.78 |
| ▸ | CERS2 | Q96G23 | 1/20 | 0.78 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.76 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20866547 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1S1PR1S1PR3S1PR4 | |
| SCHEMBL29386546 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1S1PR1S1PR3S1PR4 | |
| SCHEMBL13777285 | 0.91 | SPHK2 (0.82) | SPHK2SPHK1S1PR1S1PR3S1PR4 | |
| SCHEMBL3390328 | 0.88 | S1PR1 (1.00) | SPHK2SPHK1S1PR1S1PR3S1PR4 | |
| SCHEMBL3389578 | 0.88 | S1PR1 (1.00) | SPHK2SPHK1S1PR1S1PR3S1PR4 | |
| SCHEMBL1372656 | 0.88 | S1PR1 (1.00) | SPHK2SPHK1S1PR1S1PR3S1PR4 | |
| SCHEMBL18904548 | 0.88 | S1PR1 (1.00) | SPHK2SPHK1S1PR1S1PR3S1PR4 | |
| SCHEMBL3393539 | 0.88 | S1PR1 (1.00) | SPHK2SPHK1S1PR1S1PR3S1PR4 | |
| SCHEMBL3394797 | 0.88 | S1PR1 (1.00) | SPHK2SPHK1S1PR1S1PR3S1PR4 | |
| SCHEMBL3392313 | 0.88 | S1PR1 (1.00) | SPHK2SPHK1S1PR1S1PR3S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150258043-A1 | USE OF SPHINGOID LONG CHAIN BASES AND THEIR ANALOGS IN TREATING AND PREVENTING BACTERIAL INFECTIONS | UNIVERSITY OF DUISBURG-ESSEN (DE) | 2015-09-17 | — | — | US | claimed |
| EP-2906570-A1 | USE OF SPHINGOID LONG CHAIN BASES AND THEIR ANALOGS IN TREATING AND PREVENTING BACTERIAL INFECTIONS | Yeda Research and Development Co., Ltd. (IL) | 2015-08-19 | — | — | EP | claimed |
| WO-2014061016-A1 | USE OF SPHINGOID LONG CHAIN BASES AND THEIR ANALOGS IN TREATING AND PREVENTING BACTERIAL INFECTIONS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2014-04-24 | — | — | WO | claimed |
| US-20230321250-A1 | CANCER CELL MODULATORS | OCTAGON THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230321250-A1 | CANCER CELL MODULATORS | OCTAGON THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-11078221-B2 | Phosphorodiamidates and other phosphorus derivatives of fingolimod and related S1P receptor modulators | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2021-08-03 | — | — | US | disclosed |
| US-20200255460-A1 | PHOSPHORODIAMIDATES AND OTHER PHOSPHORUS DERIVATIVES OF FINGOLIMOD AND RELATED S1 P RECEPTOR MODULATORS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2020-08-13 | — | — | US | disclosed |
| WO-2019064012-A1 | PHOSPHORODIAMIDATES AND OTHER PHOSPHORUS DERIVATIVES OF FINGOLIMOD AND RELATED S1 P RECEPTOR MODULATORS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2019-04-04 | — | — | WO | disclosed |
| US-9220706-B2 | Inhibition of leukemic stem cells by PP2A activating agents | NATIONAL INSTITUTES OF HEALTH (NIH) (US) | 2015-12-29 | — | — | US | disclosed |
| US-9220706-B2 | Inhibition of leukemic stem cells by PP2A activating agents | NATIONAL INSTITUTES OF HEALTH (NIH) (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150258043-A1 | USE OF SPHINGOID LONG CHAIN BASES AND THEIR ANALOGS IN TREATING AND PREVENTING BACTERIAL INFECTIONS | UNIVERSITY OF DUISBURG-ESSEN (DE) | 2015-09-17 | — | — | US | disclosed |
| EP-2906570-A1 | USE OF SPHINGOID LONG CHAIN BASES AND THEIR ANALOGS IN TREATING AND PREVENTING BACTERIAL INFECTIONS | Yeda Research and Development Co., Ltd. (IL) | 2015-08-19 | — | — | EP | disclosed |
| US-20150141502-A1 | INHIBITION OF LEUKEMIC STEM CELLS BY PP2A ACTIVATING AGENTS | Ohio State Innvation Foundation (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150141502-A1 | INHIBITION OF LEUKEMIC STEM CELLS BY PP2A ACTIVATING AGENTS | Ohio State Innvation Foundation (US) | 2015-05-21 | — | — | US | disclosed |
| WO-2014061016-A1 | USE OF SPHINGOID LONG CHAIN BASES AND THEIR ANALOGS IN TREATING AND PREVENTING BACTERIAL INFECTIONS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2014-04-24 | — | — | WO | disclosed |
| US-20080108641-A1 | Compounds for treating inflammatory disorders, demyelinating disdorders and cancers | XANTHUS PHARMACEUTICALS, INC. | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321250-A1 | CANCER CELL MODULATORS | MKI67, NTPCR, TP53 | SPHK2 1124/4885SPHK1 1012/4885S1PR1 852/4885 |
| US-11078221-B2 | Phosphorodiamidates and other phosphorus derivatives of fingolimod and related S1P receptor modulators | S1PR1, S1PR3, S1PR4 | SPHK2 15/4885SPHK1 8/4885S1PR1 1/4885 |
| US-20080108641-A1 | Compounds for treating inflammatory disorders, demyelinating disdorders and cancers | PMP22, PML, AQP4 | SPHK2 248/4885SPHK1 224/4885S1PR1 127/4885 |
| US-20150141502-A1 | INHIBITION OF LEUKEMIC STEM CELLS BY PP2A ACTIVATING AGENTS | PPM1A, PPM1G, PPM1F | SPHK2 542/4885SPHK1 653/4885S1PR1 844/4885 |
| US-20200255460-A1 | PHOSPHORODIAMIDATES AND OTHER PHOSPHORUS DERIVATIVES OF FINGOLIMOD AND RELATED S1 P RECEPTOR MODULATORS | S1PR1, S1PR3, FFAR1 | SPHK2 70/4885SPHK1 21/4885S1PR1 1/4885 |
| US-20150258043-A1 | USE OF SPHINGOID LONG CHAIN BASES AND THEIR ANALOGS IN TREATING AND PREVENTING BACTERIAL INFECTIONS | SPTSSB, CFTR, SGMS1 | SPHK2 11/4885SPHK1 9/4885S1PR1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.